Changes in Bone Mineral Density and Metabolic Parameters after Pulsatile Gonadorelin Treatment in Young Men with Hypogonadotropic Hypogonadism.

Li CX, Tang ST, Zhang Q

International journal of endocrinology31 Aug 2015Cited by 8 (Europe PMC)

PMID26417369PMCIDPMC4568382DOI10.1155/2015/324524PepBankPUB-26417369

Summary

To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study. BMD, biochemical, and hormonal parameters were measured in two groups. Osteoporosis was more prevalent in HH patients (45.45%) than the control subjects (10.00%) (P < 0.001). The patients with HH had lower BMD in lumbar spine 2-4, femoral neck, and total hip (P < 0.001, for all) and higher fasting insulin (P = 0.001), HOMA-IR (P = 0.002), and SHBG (P < 0.001) compared to the controls. After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients. The study shows a higher prevalence of osteoporosis in young men with HH. Long-term pulsatile gonadorelin treatment indicates a positive effect on BMD and metabolic parameters of HH patients.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, BMI increased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, body mass index rose after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
IncreaseBMI change after pulsatile gonadorelin
Study
n = 22
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736901
02HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, bone mineral density at lumbar spine 2-4 increased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, bone density in the lower spine rose after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
IncreaseBMD at lumbar spine 2-4
Study
n = 22
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736902
03HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, bone mineral density at the femoral neck increased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, bone density at the femoral neck rose after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
IncreaseBMD at femoral neck
Study
n = 22
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736903
04HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, bone mineral density at the total hip increased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, bone density at the hip rose after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
IncreaseBMD at total hip
Study
n = 22
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736904
05HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, total cholesterol decreased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, total cholesterol fell after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseTotal cholesterol
Study
n = 22
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736905
06HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, fasting insulin decreased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, fasting insulin fell after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseFasting insulin
Study
n = 22
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736906
07HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, HOMA-IR decreased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, an insulin resistance score fell after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseHOMA-IR
Study
n = 22
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736907
08HumanNon-randomized trialEfficacy outcome
In young men with hypogonadotropic hypogonadism, SHBG decreased after 6 months of pulsatile gonadorelin treatment.
In plain wordsIn young men with hypogonadotropic hypogonadism, sex hormone binding globulin fell after 6 months of pulsatile gonadorelin.
Peptide
Gonadorelin (GnRH, LHRH)
Outcome
DecreaseSHBG
Study
n = 22
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
After 6 months of pulsatile gonadorelin treatment, BMI (P = 0.021) and BMD in lumbar spine 2-4, femoral neck, and total hip (P = 0.002, P = 0.003, and P = 0.003, resp.) increased dramatically and total cholesterol (P = 0.034), fasting insulin (P = 0.025), HOMA-IR (P = 0.021), and SHBG (P = 0.001) decreased significantly in HH patients.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the prevalence of osteoporosis in young men with hypogonadotropic hypogonadism (HH) and to investigate the changes of BMD and metabolic parameters, a total of 22 young male patients with HH and 20 healthy controls were enrolled in the study.
Show in the study text Report a problemFND-2641736908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.